Liver cancer
Conditions
Interventions
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Aged >= 18years male and female; 2. Patients with hepatocellular carcinoma who have undergone surgical resection or local ablation (PEI or percutaneous puncture or intraoperative RFA); 3. Postoperative pathology suggested no residual lesion at the cutting edge; 4. Preoperative radiology (CT, MRI, PET-CT etc), intraoperative or postoperative pathology examination revealed one risk factor for recurrence at least: Group1: Tumor number >= 3; Group2: The differentiation level is III or IV. (Edmondson-Steiner Four-stage (I-IV) classification method); Group3: The tumor thrombus of the hepatic vein, portal vein, bile duct or inferior vena cava should be visible to the naked eye or under the microscope and can be surgically removed, except for single tumor which diameter less than 2cm; Group4: AFP Elevated before surgery (>= 200ng/ml), and AFP >= 200ng/ml 1~2 months after surgery; Group5: Tumor rupture; Group6: There was no definite fibrous capsule or incomplete capsule between tumor and liver tissue; Group7: Satellite nodules are seen in the resection specimen; Group8: Special location tumor (For example: adjacent to the left, middle, right or inferior vena cava of the liver ). Group9: HBV infected persons without antiviral treatment before, or after antiviral treatment, HBV DNA > 106 copies / ml, or combined with HCV. Group10: Combined with cirrhosis. Group11: Diameter of single tumor > 5cm. 5. The investigator evaluated the possibility of receiving treatment with Camrelizumab with Apatinib 6. Voluntarily join this study and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients with known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation or planned transplantation; 2. Patients with other tumors; 3. Confirmed pregnant or lactating women; 4. Participating in any research with intervention measures outside the conventional clinical trials; 5. The investigator considered the inclusion inappropriate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Recurrence-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to recurrence;one year recurrence rate, two year recurrence rate, three year recurrence rate;Overall survival;Quality of life score;Safety; | — |
Countries
China
Contacts
Public ContactRong Liu
Chinese PLA General Hospital
Outcome results
None listed